October 2024
FDA Places Partial Clinical Hold on BioNTech’s Anti-CTLA-4 Antibody Trial
BioNTech, FDA, partial clinical hold, anti-CTLA-4 antibody, clinical trial, OncoC4
Gilead Withdraws Trodelvy for Bladder Cancer in US After Confirmatory Trial Failure
Gilead Sciences, Trodelvy, bladder cancer, urothelial carcinoma, FDA, accelerated approval, drug withdrawal
Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates
RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines
FDA Delays Decision on Full Approval for Amgen’s Lumakras and Intercept’s Ocaliva
FDA, PDUFA, Amgen, Intercept, Lumakras, Ocaliva, metastatic colorectal cancer, primary biliary cholangitis
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates Due to Rare Adverse Event
Novavax, FDA, COVID-19, Influenza, Vaccine, Clinical Hold, Motor Neuropathy
Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial
Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results
Baxter to Import 18,000 Tons of IV Fluids by Year-End Amid Ongoing Hurricane Recovery Efforts
Baxter International, IV fluid shortage, Hurricane Helene, North Carolina, importation plans, healthcare crisis
Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants
Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.
FDA Delays Decision on Amgen’s Lumakras and Vectibix Combination for Metastatic Colorectal Cancer
FDA, Amgen, Lumakras, Vectibix, metastatic colorectal cancer, KRAS G12C mutation, sotorasib, panitumumab
Terray Therapeutics Secures $120M Series B Funding to Advance AI-Driven Small Molecule Drug Development
AI-driven drug discovery, small molecule development, Terray Therapeutics, series B funding, biotechnology, pharmaceutical innovation.